The estimated Net Worth of Anish Suri is at least $4.64 millió dollars as of 25 August 2023. Anish Suri owns over 4,000 units of Cue Biopharma Inc stock worth over $80,026 and over the last 7 years he sold CUE stock worth over $0. In addition, he makes $4,559,810 as President és Chief Scientific Officer at Cue Biopharma Inc.
Sign up
Anish Suri CUE stock SEC Form 4 insiders trading
Anish has made over 12 trades of the Cue Biopharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of CUE stock worth $11,040 on 25 August 2023.
The largest trade he's ever made was exercising 33,334 units of Cue Biopharma Inc stock on 3 October 2021 worth over $19,667. On average, Anish trades about 8,449 units every 74 days since 2018. As of 25 August 2023 he still owns at least 135,638 units of Cue Biopharma Inc stock.
You can see the complete history of Anish Suri stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anish Suri biography
Dr. Anish Suri Ph.D. serves as President, Chief Scientific Officer of the Company. Prior to joining Cue Biopharma, he has held roles of increasing responsibility at Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”), most recently as Senior Director at Janssen Immunosciences in Beerse, Belgium from July 2015 to May 2018 and, prior to that, as Senior Director from January 2015 to July 2015 and as Scientific Director from April 2013 to January 2015. His core responsibilities have included providing strategic leadership and guidance for new initiatives focused on parsing the specificity and diversity of the immune repertoire to enable antigen-specific immuno-therapies and related applications in cancer immunity; tolerogenic approaches for autoimmune diseases; and harnessing immune-monitoring to enable a deeper understanding of transition states from health to disease. Dr. Suri joined Janssen from Bristol-Myers Squibb (“BMS”) in 2013, where he was responsible for providing strategic guidance to immuno-oncology and immunology drug-discovery programs. Prior to BMS, Dr. Suri was an Assistant Professor of Pathology and Immunology at Washington University School of Medicine, St. Louis. Dr. Suri received his Ph.D. in Immunology from Washington University in St. Louis.
What is the salary of Anish Suri?
As the President és Chief Scientific Officer of Cue Biopharma Inc, the total compensation of Anish Suri at Cue Biopharma Inc is $4,559,810. There are no executives at Cue Biopharma Inc getting paid more.
How old is Anish Suri?
Anish Suri is 46, he's been the President és Chief Scientific Officer of Cue Biopharma Inc since 2019. There are 16 older and 3 younger executives at Cue Biopharma Inc. The oldest executive at Cue Biopharma Inc is Frederick Driscoll, 70, who is the Independent Director.
What's Anish Suri's mailing address?
Anish's mailing address filed with the SEC is C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON, MA, 02135.
Insiders trading at Cue Biopharma Inc
Over the last 7 years, insiders at Cue Biopharma Inc have traded over $1,426,672 worth of Cue Biopharma Inc stock and bought 1,194,685 units worth $5,848,356 . The most active insiders traders include Daniel R Passeri, Aaron G.L. Fletcher és Barry J. Simon. On average, Cue Biopharma Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,162. The most recent stock trade was executed by Anish Suri on 25 August 2023, trading 4,000 units of CUE stock currently worth $11,040.
What does Cue Biopharma Inc do?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
What does Cue Biopharma Inc's logo look like?
Complete history of Anish Suri stock trades at Cue Biopharma Inc
Cue Biopharma Inc executives and stock owners
Cue Biopharma Inc executives and other stock owners filed with the SEC include:
-
Anish Suri,
President, Chief Scientific Officer -
Daniel Passeri,
Chief Executive Officer, Director -
Daniel R. Passeri M.Sc., MSc., J.D.,
CEO & Director -
Colin Sandercock,
Senior Vice President, General Counsel, Secretary -
Dr. Anish Suri Ph.D.,
Pres & Chief Scientific Officer -
Kerri-Ann Millar,
Chief Financial Officer -
Aaron Fletcher,
Independent Director -
Barry Simon,
Independent Director -
Peter Kiener,
Independent Director -
Frederick Driscoll,
Independent Director -
Frank Morich,
Independent Chairman of the Board -
Cameron Gray,
Independent Director -
Tamar Howson,
Director -
Kenneth Pienta,
Chief Medical Officer -
Kerri-Ann Millar,
Chief Financial Officer -
Dr. Kenneth J. Pienta,
Acting Chief Medical Officer -
Dr. Ronald D. Seidel III, Ph.D.,
Co-Founder -
Dr. Matteo Levisetti M.D.,
Sr. VP of Clinical Devel. -
Dr. Ronald D. Seidel III,
Exec. VP and Head of R&D -
Colin G. Sandercock J.D., MSE,
Sr. VP, Gen. Counsel & Sec. -
George B. Zavoico Ph.D.,
VP of Investor Relations & Corp. Devel. -
Dr. Steven C. Almo,
Co-Founder and Chairman of Scientific & Clinical Advisory Board -
Dr. Rodolfo J. Chaparro,
Co-Founder & Sr. Advisor -
Bethany Mancilla,
SVP and Chief Business Officer -
Ronald D. Iii Seidel,
EVP, Head of R&D -
Christopher A Marlett,
Director -
Anthony Digiandomenico,
Director -
Rodolfo Chaparro,
EVP, Head of Immunology -
Steven L Mcknight,
Director -
Patricia Nasshorn,
Chief Business Officer -
Matteo Levisetti,
Chief Medical Officer -
Michael J Fox,
-
Pamela Garzone,
-
Patrick Verheyen,
-
Lucinda Warren,
CHIEF BUSINESS OFFICER